|
|
 |
|
Viewing report
|
|
|
|
ENT Disorders Market to 2016 - Increasing Resistance to Anti-Bacterials to Drive Development of Novel Therapies for ENT Disorders
GBI Research, April 2011, Pages: 120
ENT Disorders Market to 2016 - Increasing Resistance to Anti-Bacterials to Drive Development of Novel Therapies for ENT Disorders
Summary
GBI Research’s pharmaceutical report, “ENT Disorders Market to 2016 - Increasing Resistance to Anti-Bacterials to Drive Development of Novel Therapies for ENT Disorders” provides in-depth analysis of unmet needs, drivers and barriers that impact the global ENT disorders market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments including tonsillitis, sinusitis, rhinitis and otitis media. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research finds that the ENT disorders market will continue to grow marginally. The prime reasons for slow growth of the market are the generic domination and the weak product pipelines for all the four indications. In 2009, the ENT disorders market was estimated at $16.3 billion. GBI Research forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 0.6% between 2009 and 2016.
Scope
- Annualized market data for the ENT disorders market from 2002 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis and otitis media.
- Analysis of the ENT disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Astellas Pharma, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Eli Lilly, GSK, J&J, Novartis AG, Sanofi-Aventis etc.
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global ENT disorders market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
|
|
|
|
